Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Carraro, I.M. Di Gangi, G. Piacentini, A. Kantar, S. Moser, L. Cesca, M. Berardi, G. Giordano, E. Baraldi (Padova, , Belluno, Italy). Asymmetric dimethylarginine (ADMA) in EBC of asthmatic children. Eur Respir J 2012; 40: Suppl. 56, 1098

Member's Comments

No comment yet.

Related content which might interest you: Asymmetric dimethylarginine and asthma Source: Eur Respir J 2014; 43: 647-648 Year: 2013 The role of asymmetric dimethylarginine (ADMA) in patients with asthma Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Asymmetric dimethylarginine (ADMA) in exhaled breath condensate (EBC) of children with cystic fibrosis (CF) Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Fractional exhaled nitric oxide (FeNO) in asthmatic children and their parents Source: Eur Respir J 2006; 28: Suppl. 50, 270s Year: 2006 Increased alveolar epithelial expression of dimethylarginine dimethylaminohydrolase 2 in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 823s Year: 2006 Stability of exhaled nitric oxide (FENO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008 Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Increased serum levels of IL-8 and TNFα in severe asthma compared to mild asthma: relationship with airway calibre and exhaled nitric oxide (FeNO) Source: Eur Respir J 2004; 24: Suppl. 48, 351s Year: 2004 High levels of fractional exhaled nitric oxide (FeNO) in severe oral steroid-dependent asthma are associated with eosinophilia and atopy Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009 FeNO (fractional exhaled nitric oxide) measurements in pregnant asthmatic women. The long-term, intra-subject variability of FeNO in controlled asthma Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Exhaled nitric oxide (eNO) levels in asthmatic children: relation to atopy and airway responsiveness (AHR) Source: Eur Respir J 2004; 24: Suppl. 48, 271s Year: 2004 Gender differences in exhaled nitric oxide concentrations (FeNO) in healthy individuals Source: Eur Respir J 2001; 18: Suppl. 33, 258s Year: 2001 Increased exhaled 8-isoprostane in childhood asthma Source: Eur Respir J 2002; 20: Suppl. 38, 141s Year: 2002 Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 677s Year: 2006 Exercise-induced bronchoconstriction (EIB) is not associated with exhaled nitric oxide (FeNO) in adolescent athletes Source: International Congress 2019 – Asthma biomarkers, diagnostics and risk factors Year: 2019 Relationship between exhaled nitric oxide (eNO), atopy and asthma in children. ISAAC-clermont-ferrand Source: Eur Respir J 2001; 18: Suppl. 33, 38s Year: 2001 Serum nitrotyrosine and nitric oxide levels in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002 Exhaled nitric oxide (FeNO) in relation to exacerbation of childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009